Published in
Taylor and Francis Group, Expert Opinion on Drug Safety, 11(19), p. 1513-1520, 2020
DOI: 10.1080/14740338.2020.1798928
Links
Tools
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice
Journal article published in 2020 by
Luis Alberto García-Rodríguez 
,
Mari-Ann Wallander ,
Leif Friberg ,
Ana Ruigomez ,
Tania Schink ,
Irene Bezemer ,
Ron Herings ,
Saad Shakir ,
Alison Evans ,
Miranda Davies ,
Kiliana Suzart-Woischnik ,
Pareen Vora ,
Yanina Balabanova ,
Montse Soriano-Gabarró ,
Gunnar Brobert
,
Mari-Ann Wallander ,
Leif Friberg ,
Ana Ruigomez ,
Tania Schink ,
Irene Bezemer ,
Ron Herings ,
Saad Shakir ,
Alison Evans ,
Miranda Davies ,
Kiliana Suzart-Woischnik ,
Pareen Vora ,
Yanina Balabanova ,
Montse Soriano-Gabarró ,
Gunnar Brobert
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 